Clinical Trial Update: Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral Haemorrhage [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and preliminary efficacy of activated recombinant human factor VII in acute intracerebral hemorrhage has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intracerebral Hemorrhage

Drugs mentioned

• NovoSeven (recombinant coagulation factor VIIa)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Acquired Bleeding Disorder, Intracerebral Haemorrhage | Phase 2 | Status: COMPLETED